Kornimate/medical-research-clean huggingface dataset:
study of coronary heart disease (chd) & heart failure (hf) risk in prostate cancer patients, taking casodex or not

Conditions: Prostate Cancer

Summary: a retrospective cohort study performed in the gprd,uk. all patients with incident prostate cancer identified between 1 jan 1999 and 31 dec 2005 and a frequency-matched cohort of the general population will be followed- up for two outcomes; chd including acute myocardial infarction or death from coronary heart disease and hf until dec 31, 2006. outcomes will be validated through requests to primary care physicians. incidence rate´ratios of chd and hf in the two cohorts will be calculated. in the cohort of prostate cancer the relative risk of chd and hf associated with the use of bicalutamide compared to non-use will be estimated.


Eligibility criteria:
inclusion criteria: * at least two years enrollment with the general practitioner exclusion criteria: * patients with cancer before start date of the study

Keywords: prostate cancer pharmacoepidemiology study
study of the intervention effect of self-help training camps in promoting mental health among perinatal women

Conditions: Mental Health; Perinatal Depression

Summary: this study was a multi-center randomized controlled trial of an internet-based self-help mental fitness training camp intervention that included women in early, mid, and late pregnancy with or without psychological distress. a comparison was conducted between the intervention and control groups with regard to depression and anxiety scores during pregnancy and at 42 days postpartum in order to ascertain the efficacy of a self-help mental fitness training camp in preventing negative emotions among perinatal women. in addition, associations between different modes of intervention and maternal and infant outcomes were investigated.

in this study, the principle of "early detection, early diagnosis and early treatment" was used to screen and manage negative emotions such as anxiety and depression in three time windows: early pregnancy, mid-pregnancy and late pregnancy. all weeks from june to december 2024 were randomly divided into intervention and control weeks. pregnant women were assigned to the intervention or control group according to the week of their visit to the hospital for obstetric examination. the intervention group of pregnant women participated in a three-week program of mental fitness training, while the control group received standard care. the participants were evaluated on multiple occasions following their enrollment in the study. these evaluations occurred at the baseline stage, immediately following the intervention, during the mid and late stages of pregnancy, and 42 days after delivery.

Eligibility criteria:
inclusion criteria: * pregnant women * the gestational week in early pregnancy is 0 to 13 weeks; the gestational week in mid-pregnancy is 14 to 27 weeks; and the gestational week in late pregnancy is 28 to 32 weeks. * intention to have children in this pregnancy. * ability to understand and complete the questionnaire independently. * informed consent and voluntary participation in this study. exclusion criteria: * suffering from depression being treated with psychotherapy or medication. * the presence of a serious mental illness or intellectual disability.
minocycline augmentation of clozapine for treatment resistant schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder

Summary: this a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to treatment resistant schizophrenia (trs).

the primary objective is to determine if the addition of minocycline to clozapine, treatment as usual (tau) improves negative symptoms and/or positive symptoms. the secondary objectives are to determine: * effects on cognitive functioning. * effects on social functioning and quality of life. * safety and tolerability. * possible additive effects of minocycline added to tau * the effect on inflammatory biomarkers associated with schizophrenia. both pro and anti-inflammatory cytokines will be drawn at baseline and endpoint. we will test to see if minocycline is associated with improvements in abnormal cytokines as compared to placebo. the study will be a randomized double-blind placebo controlled trial of minocycline added to clozapine (treatment as usual) in trs. there will be two treatment arms: one arm receiving tau with minocycline and the other tau with placebo for a period of twelve weeks.

Eligibility criteria:
inclusion criteria: * male and female patients aged between 18-65 years, iq \>70 (to complete assessments) identified by treating psychiatrist. * confirmation of schizophrenia by using the mini psychiatric interview (at baseline only) * assessed as competent to provide informed consent by treating psychiatrist. * antipsychotic medication has remained stable 4 weeks prior to baseline \*. assessed as a partial responder to clozapine: patients prescribed clozapine at a stable therapeutic dose for a minimum of 3 months with total positive and negative syndrome schizophrenia (panss) score \>70. exclusion criteria: * prior history of intolerance or serious side effects (hepatotoxicity, photosensitivity, blood dyscrasias) to any of the tetracyclines. * concomitant penicillin therapy or concomitant anticoagulant therapy. * active substance abuse (except nicotine or caffeine) or dependence within the last three months according to icd 10 criteria. * treatment with warfarin or lamotrigine. * current or previous treatment with minocycline or other tetracycline antibiotics in the preceding three months before study entry. * relevant current or past hematologic, hepatic, renal, neurological or other medical disorder that in the opinion of the principal investigator may interfere with the study. * pregnant or breast-feeding females

Keywords: schizophrenia anti-inflammatory clozapine minocycline psychosis nos
deep learning-enhanced personalized monitoring of aortic stenosis - the detect-as prognostic study

Conditions: Aortic Stenosis

Summary: this study will evaluate the validity of a digital biomarker score for precision risk stratification among older adults with aortic sclerosis or mild aortic stenosis (as) at three us health systems.


Eligibility criteria:
inclusion criteria: 1. age 65 years or older 2. prior transthoracic echocardiogram within the past 2-3 years showing aortic sclerosis without stenosis or mild as exclusion criteria: 1. opted out of research studies 2. non-english speaking 3. any echocardiogram within 24 months of medical record review. 4. prior history of aortic valve replacement or repair, including transcatheter and surgical avr with either a bioprosthetic or mechanical valve 5. presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device 6. prior heart transplant 7. history of dementia 8. unable to attend study visit at echocardiogram lab within four years of most recent echocardiogram. 9. documented life expectancy of \<1 year or current participation in hospice services

Keywords: aortic stenosis artificial intelligence
pharmacokinetics - pharmacodynamic study of ht-2157 in healthy subjects and in patients with major depressive disorder

Conditions: Healthy Volunteers (Part 1); Major Depressive Disorder (Part 2)

Summary: this is a two part study. the objective of part 1 is to evaluate the safety, tolerability, and pharmacokinetics of ht-2157 in healthy normal volunteers part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day) ascending-dose evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ht-2157 in patients with major depressive disorder

this is a two part study. the objective of part 1 is to evaluate the safety, tolerability, and pharmacokinetics of ht-2157 administered for 7-days in healthy normal volunteers part 2 is a randomized, double-blind, placebo-controlled, multiple ascending-dose evaluation of the safety, tolerability, pharmacokinetics of ht-2157 administered for 21-days in patients with major depressive disorder. the primary objective of part 2 is to assess the cns penetration of ht-2157 in cerebrospinal fluid. in addition, the potential activity of ht-2157 in this patient population may be assessed using exploratory biologic and pharmacodynamic markers of potential efficacy

Eligibility criteria:
main inclusion criteria (part 1) * no clinically relevant abnormalities * age 18 to 55 years, inclusive * body mass index (bmi) of 18.5 to 32 kg/m2 main inclusion criteria (part 2) * no clinically relevant abnormalities * age 18 to 55 years, inclusive * body mass index (bmi) of 18.5 to 32 kg/m2 * mild-to-moderate major depressive disorder main exclusion criteria (part 1) - any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs main exclusion criteria (part 2) * any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs * current and primary axis i disorder other than mdd
docetaxel +/- suramin in 2nd line advanced non-small cell lung cancer

Conditions: Carcinoma, Non Small Cell Lung

Summary: the overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

the overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings. secondary objectives include: * to compare response rate of patients in both treatment arms * to compare overall survival of patients in both treatment arms * to compare toxicity in both treatment arms * to determine whether the survival benefit from suramin is associated with reduced m-phase entry in peripheral blood lymphocytes

Eligibility criteria:
inclusion criteria: * pathologically proven diagnosis of non-small cell lung cancer * documented disease progression after first-line chemotherapy for non-small cell lung cancer * stable and treated cns metastasis is allowed * radiation must be completed at least 2 weeks prior to starting protocol treatment * major surgery must be completed at least 4 weeks prior to starting protocol treatment * ecog performance status 0-2 * sexually active patients must use adequate contraception * adequate bone marrow function * adequate renal function * adequate liver function exclusion criteria: * severe hypersensitivity reaction to docetaxel * pre-existing grade 3 or 4 neuropathy * women who are pregnant or breastfeeding * uncontrolled intercurrent illness * receipt of 3 or more prior chemotherapy regimens

Keywords: carcinoma, non small cell lung second line third line
perception of the risks of alcohol and individual vulnerabilities in young adults

Conditions: Alcohol Abuse

Summary: alcohol use is the second leading cause of preventable death after smoking. the evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. but this law is currently extremely weakened, and in a press release of february 26, 2018, the french society of alcoology is alarmed by these developments. studies focusing on the impact of alcohol marketing focus largely on young adolescents, and the links between exposure to marketing and the initiation of alcohol. but beyond these links, there has been little work on the impact of alcohol marketing in vulnerable subjects with regular alcohol consumption. consumption of alcohol is one of the first causes of hospitalization in france (paille and reynaud, 2015), the damage is often restricted to notions of dependency risks, but they can appear as soon as consumptions of 1 us / d (guerin and laplanche, 2013) and they mainly concern 45-64 year olds. to our knowledge, there are no studies on the impact of alcohol marketing conducted on regular alcohol users, depending on how they use alcohol (use, or use disorders). mild, moderate or severe) in patients enrolled in primary care and specialized addiction care.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 45 years with moderate or severe alcohol use disorders * followed in addiction at brest chru exclusion criteria: * major from 18 to 45 years * current consumption of alcohol (multi-monthly) * follow-up in primary care or addictology in brest

Keywords: regular consumption of alcohol young adults moderate or severe alcohol use disorders
screening of patients with hepatic fibrosis or cirrhosis b and c

Conditions: Liver Pathology

Summary: regardless of its etiology (chronic hepatitis b or c, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue. cirrhosis is a chronic disease and can get complicated by liver cancer, digestive hemorrhage, or liver failure, which are responsible for morbidity and mortality. in france, cirrhosis prevalence is estimated at 700,000 patients and induce 16,000 deaths per year (10,000 liver cancer and 6,000 liver decompensation). in ile-de-france area, cirrhosis prevalence is estimated at 130,000 cases, a lot of them are in seine saint denis department due to precariousness. hepatitis c virus can now be cured and hepatitis b treatment can suspend hepatitis b replication. all these treatments reduce liver complications but even after virological cure, cirrhosis requires dedicated long term management as well as alcoholic liver disease and metabolic steatohepatitis at cirrhosis stage. periodic screening for complications and specific measures were defined by french has in 2007 (medication intake, dietary management and specific vaccinations), especially the performance of a semi-annual liver ultrasound for hepatocellular carcinoma (hcc) screening. then, it seems essential to screen for patients with viral hepatitis and extensive fibrosis or cirrhosis in our department to achieve active and individualized management of this chronic liver disease, to reduce long term morbidity and mortality. the main aim of the study is to evaluate the prevalence of advanced liver fibrosis and viral infections b and c in the general population of seine saint denis, using a dual screening method of trod (rapid diagnostic orientation test) and fibroscan®, combined with a care pathway

targeted population the targeted population will be users of one municipal health center visiting the municipal health center on a given day we will propose a screening for liver fibrosis using fibroscan mini® and will propose rapid diagnostic orientation tests (trod) for hcv and hbv viral infection, by a traveling physician expérimental scheme proposal by the caregiver to each patient at the center : * fibroscan® * trod vhc / vhb if fibroscan ≥ 9.6 kpa or positive hcv trod or hbsag positive then suggested appointment avicenne hospital hepatology consultation or jean verdier hepatology consultation

Eligibility criteria:
inclusion criteria: * age≥18 years * collection of signed consent * patients affiliated to a social security system exclusion criteria: * pregnancy or breastfeeding * subjects under ame * persons under court protection * guardianship or curatorship, * safeguard of justice * persons under psychiatric care without their consent * persons admitted to a health or social institution for purposes other than research, * patients of full age under legal protection (guardianship or curatorship) * persons unable to express their consent.

Keywords: cirrhosis, liver hepatic cirrhosis liver fibrosis fibrosis
fireworks eye injuries during festivals in upper egypt

Conditions: Ocular Injury; Blast Injuries

Summary: the aim of this study is to explore and report the epidemiology and outcome of fireworks ocular injuries in upper egypt. primary outcome : type and severity of injury of fireworks eye trauma during festives. secondary outcome: demography, complications, and final visual outcome of fireworks eye injury.


Eligibility criteria:
inclusion criteria: * patients attending ocular emergency unit with fireworks eye injury during different festivals in 2024 exclusion criteria: * patients presented with non-fireworks ocular injuries
myeloma treatment in real life

Conditions: Multiple Myeloma

Summary: as part of an oral treatment regimen in ambulatory practice, certain uses in connection with drug consumption associated could alter treatment outcomes observed in randomized clinical trials. the increase in progression-free survival in myeloma may be accompanied by an impaired quality of life and a resurgence of pain symptoms over time, which could potentially lead to medication overuse involving painkillers but also psychotropic drugs. these combined consumption may affect survival through mechanisms of pharmacological or non-pharmacological interactions. as part of this project, we wish to explore the scheme of adherence to myeloma drugs, and thus validate the decision diagram of hypothesis of not adequate of drug use in ambulatory conditions, from observational data. this discrepancy could result from poor adherence or suboptimal drug use but also from concomitant exposures to other drugs which may interact with myeloma. before considering a study of greater magnitude that could address the consequences of non optimal drug use on clinical response criteria, such as duration of response or survival, it seems appropriate to confirm these assumptions within ' an exploratory study.


Eligibility criteria:
inclusion criteria: * beneficiaries or entitled to health insurance or covered by the national system of information of health insurance * identified as multiple myeloma * incident patient : subject presenting none of inclusion criteria during the 6 months observation period exclusion criteria: * non incident patient : subject presenting at least one of inclusion criteria during the 6 months observation period

Keywords: drug consumption response to treatment non optimal drug use
lifeline-net (narrative exposure therapy): a short-term treatment for traumatized refugees and asylum seekers

Conditions: Trauma Treatment; Lifeline NET; Modification of Narrative Exposure Therapy

Summary: evaluation of a short version of narrative exposure therapy


Eligibility criteria:
inclusion criteria: * ptsd exclusion criteria: * psychotic disorder, * severe substance dependence
sitagliptin mechanism of action study in patients with type 2 diabetes mellitus (0431-059)

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: a clinical study to determine the safety, efficacy and the way sitagliptin works in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.


Eligibility criteria:
inclusion criteria: * participant has type 2 diabetes mellitus * males * females who are highly unlikely to become pregnant * participants poorly controlled without taking any, or taking one or two oral antidiabetic medications exclusion criteria: * participant has a history of type 1 diabetes mellitus or history of ketoacidosis * participant required insulin therapy within the prior 8 weeks * participant is on or has been taking tzds such as actos® (pioglitazone) or avandia® (rosiglitazone) within the prior 12 weeks of the screening visit
the immunogenicity and safety of live attenuated poliomyelitis vaccine (human diploid cell)

Conditions: Poliomyelitis

Summary: the purpose of this phase 2/3 trial is to assess the safety and immunogenicity of live attenuated poliomyelitis vaccine (human diploid cell)

live attenuated poliomyelitis vaccine (human diploid cell) is used for poliovirus prevention in children above 2 years old , which was developed by institute of medical biology , chinese academy of medical sciences , based on the other two products : poliomyelitis vaccine in dragee candy (monkey kidney cell), live ; and poliomyelitis（live）vaccine (monkey kidney cell),oral . after its safety been proved in phase 1 clinical trail evaluation , the phase 2/3 trail was started in guangxi province, china during 2011-2012. the purpose of this trial is to assess the safety and immunogenicity in healthy children of 2,3 and 4 months old .

Eligibility criteria:
inclusion criteria:only subjects fulfilling all of the following criteria will be eligible for the study: * people aged from 2 months to 4 months old. * the subjects or subjects' guardians are able to understand and sign the informed consent * the subjects or subjects' guardians allow to comply with the requirements of the protocol * subjects with temperature \<=37.0°c on axillary setting * the subjects have signed informed consent already exclusion criteria:the subjects have never been vaccinated with any poliomyelitis vaccine. -

Keywords: poliomyelitis vaccine safety efficacy
psychosocial intervention in latino patients with advanced cancer

Conditions: Advanced Cancer

Summary: palliative care focuses on symptom management and quality of life and helps patients with life-limiting illness match goals and preferences for care. while there has been interest in and acknowledgement that palliative care is an important part of training patient navigators, there have been no previous studies examining the effectiveness of a navigation intervention to improve palliative care for patients. this study will examine the feasibility to implement patient navigator and psychosocial interventions.


Eligibility criteria:
inclusion criteria: * adults ages \> or = 18 years of age * must self-identify as latino/a * have stage iii/iv cancer * seeking or in treatment for their cancer (ie: not in hospice care) * not incarcerated * have at least moderate baseline distress (\> 4 on the nccn distress thermometer) or positive screen for depression (phq-2 score \>=3) or anxiety (gad-2 score \>=3) exclusion criteria: -no exclusion criteria listed

Keywords: palliative care latino psychosocial intervention patient navigation